...
首页> 外文期刊>Arteriosclerosis, thrombosis, and vascular biology >Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated downregulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase expression.
【24h】

Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated downregulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase expression.

机译:贝特类药物通过过氧化物酶体增殖物激活的受体-α介导的胆固醇7α-羟化酶和固醇27-羟化酶表达的下调来抑制胆汁酸的合成。

获取原文
获取原文并翻译 | 示例

摘要

Fibrates are hypolipidemic drugs that affect the expression of genes involved in lipid metabolism by activating peroxisome proliferator-activated receptors (PPARs). Fibrate treatment causes adverse changes in biliary lipid composition and decreases bile acid excretion, leading to an increased incidence of cholesterol gallstones. In this study, we investigated the effect of fibrates on bile acid synthesis. Ciprofibrate and the PPARalpha agonist Wy14,643 decreased bile acid synthesis in cultured rat hepatocytes and suppressed cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase activities, paralleled by a similar reduction of the respective mRNAs. Treatment of rats with 0.05% (wt/wt) ciprofibrate decreased cholesterol 7alpha-hydroxylase enzyme activity and mRNA. The functional involvement of PPARalpha in the suppression of both enzymes was proven with the use of PPARalpha-null mice. In wild-type mice, ciprofibrate reduced cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase enzyme activities and mRNA. The decrease in mRNA of both enzymes is regulated transcriptionally and posttranscriptionally, respectively, resulting in a decline in the output of fecal bile acids (-45%) and a 3-fold increase in fecal cholesterol secretion. These effects were completely abolished in PPARalpha-null mice. A decreased bile acid production by PPARalpha-mediated downregulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase may contribute to the increased risk of gallstone formation after fibrate treatment.
机译:贝特类是降血脂药,通过激活过氧化物酶体增殖物激活受体(PPAR)影响脂质代谢相关基因的表达。纤维蛋白治疗会导致胆汁脂质成分发生不利变化,并降低胆汁酸的排泄,从而导致胆固醇胆结石的发生率增加。在这项研究中,我们研究了贝特类药物对胆汁酸合成的影响。环丙贝特和PPARalpha激动剂Wy14,643减少了培养的大鼠肝细胞中的胆汁酸合成,并抑制了胆固醇7α-羟化酶和固醇27-羟化酶的活性,同时相应地降低了各自的mRNA。用0.05%(wt / wt)环丙贝特处理大鼠会降低胆固醇7α-羟化酶的活性和mRNA。 PPARalpha-null小鼠的使用证明了PPARalpha在抑制这两种酶中的功能。在野生型小鼠中,环丙贝特降低胆固醇7α-羟化酶和固醇27-羟化酶的活性和mRNA。两种酶的mRNA降低分别在转录和转录后受到调节,导致粪便胆汁酸的产量下降(-45%),粪便胆固醇分泌增加3倍。这些影响在PPARalpha-null小鼠中被完全消除。通过PPARalpha介导的胆固醇7α-羟化酶和固醇27-羟化酶的下调,胆汁酸的产生减少可能会导致贝特类药物治疗后胆结石形成的风险增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号